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Abstract
Background. Tinnitus is a serious late effect of childhood cancer treatment. The aim of this study was to determine 
the occurrence and risk factors for tinnitus in a national cohort of childhood cancer survivors (CCS).
Methods. Data were collected within the national Dutch Childhood Oncology Group - Long-Term Effects after 
Childhood Cancer (DCOG-LATER) cohort by a self-reported health questionnaire among 5327 Dutch CCS treated be-
tween 1963 and 2002. Siblings (N = 1663) were invited to complete the same questionnaire. Relevant patient charac-
teristics and treatment factors were obtained from the Dutch LATER database. The occurrence of tinnitus in survivors 
was compared to siblings. To study the effect of risk factors, multivariate logistic regression models were estimated.
Results. In total, 2948 CCS and 1055 siblings completed the tinnitus item. Tinnitus was reported in 9.5% of sur-
vivors and in 3.7% of siblings (odds ratio [OR] 3.0, 95% confidence interval [CI] 2.9–3.1). Risk factors associated 
with tinnitus in CCS were total cumulative dose cisplatin ≥400 mg/m2 (OR 2.4, 95% CI 1.4–4.0), age at diagnosis 
(≥10 years: OR 2.1, 95% CI 1.6–2.8), cranial irradiation/total body irradiation (TBI; OR 1.9, 95% CI 1.5–2.5), and neuro/
ear, nose, throat (ENT) surgery (OR 1.8, 95% CI 1.1–2.9). Fifty-one percent of CCS with tinnitus had received treat-
ment with either cisplatin, cranial irradiation/TBI, and/or neuro/ENT surgery.
Conclusions. Tinnitus in CCS was present nearly 3 times more often than in siblings. Awareness in CCS previously 
treated with cisplatin, cranial irradiation/TBI, and/or neuro/ENT surgery is warranted. As only half of affected CCS had a 
history of these treatments, it seems that other factors might be associated with tinnitus occurrence in this population.
Risk factors associated with tinnitus in 2948 Dutch 
survivors of childhood cancer: a Dutch LATER 
questionnaire study
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Key Points
 • Childhood cancer survivors are at higher risk for tinnitus compared to siblings.
 • Cisplatin, cranial irradiation, and CNS surgery are risk factors for tinnitus.
 • Tinnitus screening after childhood cancer deserves serious attention.
Over the past decades, outcome of childhood cancer has 
improved considerably.1 However, improvement in sur-
vival is associated with the development of late toxicities, 
among others due to increased treatment intensity. About 
75% of childhood cancer survivors (CCS) suffer from one 
or more adverse events.2,3 Long-term morbidity after child-
hood cancer includes ototoxicity, which comprises damage 
to the cochlea resulting in permanent hearing loss, a condi-
tion often accompanied by tinnitus.4 Both hearing loss and 
tinnitus can have a severe negative impact on quality of life. 
Hearing loss impacts speech discrimination, resulting in de-
creased learning and social performance.5 Tinnitus can have 
an (additional) negative effect by causing stress, problems 
with coping, and diminished concentration.6
Compared to hearing loss, tinnitus is a less often investi-
gated side effect after childhood cancer treatment. Patients 
with tinnitus suffer from ringing, buzzing, or hissing sounds 
in their ear or head that cannot be perceived by others. Its se-
verity and accompanying symptoms vary between affected 
individuals.7 Currently, multiple hypotheses exist on mechan-
isms for tinnitus development. A recent understanding is that 
following cochlear or neural damage, neurons in the dorsal 
part of the cochlear nucleus (DCN) respond by upregulating 
both spontaneous and sound-evoked neural activity. This 
increase in spontaneous activity is caused by unbalanced 
excitatory and inhibitory nerve transmission, which leads to 
an increased firing rate of neurons and eventually to the per-
ception of tinnitus. It is believed that damage to cochlear hair 
cells due to cisplatin may cause increased DCN activity.8
Audiological monitoring for hearing loss has become 
part of standard care during childhood cancer treatment, 
and recently international consensus was reached for 
hearing loss surveillance in CCS. In contrast, tinnitus as a 
late effect of childhood cancer treatment has not obtained 
major attention so far, and the lack of knowledge on prev-
alence and risk factors in survivors has been acknowl-
edged.9 Therefore, in the current study, we studied the 
occurrence of tinnitus in a national cohort of CCS in com-
parison with healthy siblings and identified patient and 
treatment-related risk factors associated with the occur-
rence of tinnitus in CCS.
Materials and Methods
Study Population
Data for this cross-sectional study were collected within 
the Dutch Childhood Oncology Group - Long-Term Effects 
after Childhood Cancer (DCOG-LATER) study, a national 
study that has been set up to gain more insight into all 
long-term side effects of treatment among the earliest co-
hort of 6165 Dutch CCS. Included subjects were diagnosed 
with cancer before the age of 18 years, (co-)treated in 1 of 
the 7 pediatric oncology centers from 1963 to 2002, and 
alive (more than) 5 years after diagnosis. The characteris-
tics of this cohort have been previously described.10
As part of this national study, a general health question-
naire was sent out between 2014 and 2016 to all eligible 
CSS alive in 2013. This list contained questions on current 
and past health status, family history, medication use, 
smoking, alcohol and drug habits, as well as physical ac-
tivity. In addition, the questionnaire included queries on 
tinnitus and hearing aid use. Healthy siblings who were 
signed up by the survivors served as the control group 
for this study. They were asked to complete the same 
questionnaire.
Importance of the Study
Tinnitus is a serious late effect of childhood 
cancer treatment. Even though tinnitus can 
have a considerable impact on the quality of 
life, the disorder has not obtained major atten-
tion in survivorship care. This is disturbing, as 
tinnitus can result in sleeping difficulties, anx-
iety, depression, and even sporadically to self-
harm and suicide. Studies on prevalence and 
risk factors of tinnitus after childhood cancer 
treatment are limited. The results of this study 
are important to increase awareness for tinnitus 
among clinicians and to identify groups of child-
hood cancer survivors at high risk of developing 
tinnitus. Our study may also facilitate the de-
sign of regular screening recommendations for 
the disorder along with audiological checkups 
in late effect clinics and in the long run lead to 
changes in treatment strategies to decrease tin-
nitus. Regular surveillance aids in (early) detec-
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Among the 6165 survivors, 838 were ineligible for the 
study. Of the remaining 5327 eligible survivors, 3369 
(63%) agreed to participate, and 3169 (59%) returned the 
general health questionnaire. Among the 1746 siblings, 
84 were ineligible for the survey. Of the remaining 1662 
siblings, 1080 (65%) agreed to participate in the study, 
and 1072 (64.5%) returned the general health question-
naire (Figure 1).
The study was approved by the medical ethics boards of 
all participating centers. Informed consent was obtained 
from all participants before study inclusion.
Outcome Measures
The questionnaire included one item on tinnitus, which 
was the primary outcome of interest. The question was 
“have you had ringing in the ears, or do you currently have 
this condition?” (yes/no). A  second item ascertained the 
use of a hearing aid, as follows: “have you had a hearing 
aid, or do you currently have one?” (yes/no). Survivors and 
siblings were also asked to fill out the age or year of tin-
nitus onset and start to wear a hearing aid. The question-
naire did not capture questions on the presence of hearing 
loss because this was difficult to define for self-reported 
data.
Treatment Information
Data on childhood cancer subtype, gender, age at diag-
nosis, relevant chemotherapy, surgery, and radiotherapy 
were extracted from the Dutch LATER database on diag-
nosis and treatment. Detailed information on 45 different 
types of chemotherapy with total cumulative doses (TCDs) 
in mg/m2 was available. These agents were grouped 
into 6 categories (ie, alkylating agents, anthracyclines, 
platinum agents, vinca-alkaloids, antimetabolites, and 
epipodophyllotoxins). CCS who received radiotherapy 
were assigned to one of the 2 subgroups: cranial irradia-
tion/total body irradiation (TBI) or irradiation to a body 
site other than the brain or skull. Data on the total irradi-
ation dose were captured in gray (Gy). Dose reconstruc-
tions for structures in the ear were not included as they 
were not available. Information on surgery was reviewed 
and divided into 3 categories: surgery on head/cranium 
(including brain surgery and ventriculostomy), ear, nose, 
throat (ENT) surgery (including stapedectomy, myrin-
gotomy, and tympanoplasty), and surgery to any other 
body site.
Data Analysis
Descriptive statistics included medians along with range, 
and frequencies with percentages were provided for con-
tinuous and categorical variables, respectively. Occurrence 
of self-reported tinnitus (in %) was compared between sur-
vivors and siblings. Chi-square tests and Mann–Whitney 
U tests were used to compare clinical characteristics be-
tween CCS and siblings.
Generalized estimating equation models were estimated 
to study the association between tinnitus occurrence in 
CCS compared to siblings. These models account for the 
presence of correlation between siblings. The models were 
adjusted for gender and age at the time of questionnaire. 
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N = 582 (35%)
Ineligible siblings (N = 84)
Ineligible CCS (N=838)
Deceased (N = 611)
Lost to follow-up (N = 35)
Living abroad (N = 142)
Minor sibling, no consent parent
(N = 47)
Sibling age < 12 years (N = 12)
Survivor deceased (N = 11)
Survivor excluded from DCOG-
LATER cohort (N = 3)
Other (N = 11)Refused any contact by LATER (N = 45)
Other (N = 5)
Figure 1. Flowcharts showing the eligibility of CCS and siblings for the general health questionnaire, and representability of those who completed 
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Logistic regression models were employed to identify 
risk factors associated with tinnitus in CCS. Variables with 
a P value of less than .20 in the univariate analyses were 
included in multivariate analyses. Forward method was 
applied to estimate the final logistic regression models. 
All variables associated with tinnitus with a P value of 
less than .05 were included in the final model. ORs along 
with their 95% CIs were estimated. Gender (male/female), 
age at diagnosis (<5  years, 5–9  years, 10+ years), cra-
nial irradiation/TBI (yes/no), neuro/ENT surgery (yes/no), 
and platinum agents (cisplatin and carboplatin, yes/no) 
were included in one model. The TCDs of platinum agents 
and the total irradiation doses were analyzed as dichoto-
mous variables in a second model. Cutoff points were 
based on the literature9,11,12 and dose–response analysis 
(Supplementary Table 1).
Furthermore, we compared CCS with tinnitus who had 
and had not received ototoxic cancer treatment, and CCS 
without tinnitus with respect to patient and treatment char-
acteristics. For an in-depth search of risk factors, univariate 
and multivariate logistic regression models were esti-
mated separately for the 2 largest subpopulations of the 
DCOG-LATER cohort consisting of acute lymphoblastic leu-
kemia (ALL) survivors and central nervous system (CNS) 
tumor survivors.
All statistical analyses were performed using SPSS soft-
ware version 25 (SPSS Inc.).
Results
Cohort Characteristics
In total, 2948/3169 (93%) CCS and 1055/1072 (98%) sib-
lings completed the query on tinnitus in the general health 
questionnaire (Figure  1). Survivors who completed the 
tinnitus item were representative of the total cohort of el-
igible CCS concerning the age at diagnosis, gender, plat-
inum agents, neuro/ENT surgery, and cranial irradiation/
TBI (Supplementary Table 2).
The median age of CCS at the time of cancer diagnosis 
was 5.3 years (range 0–18), and the median time from di-
agnosis to questionnaire completion was 22.4 years (range 
11–50; Table  1). Most of the CCS had been diagnosed 
with ALL (N = 888, 30%) and CNS tumors (N = 353, 12%). 
Siblings were more often female (P < .001) and older (more 
often >20 years of age) at time of questionnaire (P < .001) 
compared to CCS.
In total, 1968/2948 (67%) survivors underwent surgery, 
of whom 150 (8%) were carried out on head/cranium or 
ear (Table  2). Chemotherapy had been administered to 
2472/2948 (84%) survivors, of which 374 (15%) received 
platinum agents. Radiotherapy had been administered to 
1147/2948 (39%) CCS. Among these irradiated patients, 698 
(61%) received cranial irradiation/TBI.
Occurrence of Tinnitus in CCS Compared to 
Siblings
Tinnitus occurred in 280/2948 (9.5%) CCS compared to 
40/1055 (3.7%) in siblings (Table 1). Age at tinnitus onset 
  
Table 1. Baseline Characteristics of CCS Who Answered the 








   
  Acute lympho-
blastic leukemia
888 (30.0) NA (NA)  
  Acute myeloid 
leukemiaa
132 (4.5) NA (NA)  
  Non-Hodgkin 
lymphomab
329 (11.1) NA (NA)  
 Hodgkin lymphoma 186 (6.3) NA (NA)  
  Central nervous 
system tumors
353 (12.0) NA (NA)  
 Neuroblastoma 162 (5.5) NA (NA)  
 Retinoblastoma 14 (0.5)  NA (NA)  
 Renal tumors 326 (11.1) NA (NA)  
 Hepatic tumors 32 (1.1) NA (NA)  
 Osteosarcoma 86 (2.9) NA (NA)  
  Ewing sarcoma/
other bone tumors
81 (2.8) NA (NA)  
 Soft tissue tumors 210 (7.1) NA (NA)  
 Germ cell tumors 108 (3.7) NA (NA)  
  Other and unspeci-
fied tumors
41 (1.4) NA (NA)  
Age at diagnosis in 
years, n (%)
   
 <5 1379 (46.8) NA (NA)  
 5–9 789 (26.8) NA (NA)  




   
 1963–1984 883 (30.0) NA (NA)  
 1985–1994 1058 (35.9) NA (NA)  
 1995–2001 1007 (34.2) NA (NA)  
Time since diagnosis 
to questionnaire in 
years, n (%)
   
 <20 1207 (40.9) NA (NA)  
 20–29 433 (14.7) NA (NA)  
 30–39 310 (10.5) NA (NA)  
 40+ 108 (3.7) NA (NA)  
Age at questionnaire 
in yearsc, n (%)
  <.001
 <20 489 (16.6) 115 (11.0)  
 20–29 1023 (34.7) 343 (32.8)  
 30–39 920 (31.2) 341 (32.6)  
 40+ 516 (17.5) 248 (23.5)  
Gender, n (%)   <.001
 Male 1523 (51.7) 446 (42.3)  
 Female 1425 (48.3) 609 (57.7)  
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was available for 146/280 (52%) survivors and 34/40 (85%) 
siblings. Median age of tinnitus onset in CCS was 25 years 
(range 4–54) and in siblings 35 years (range 5–53). Among 
these survivors, the median time from diagnosis to tinnitus 
onset was 15 years (range 0–39). The OR for tinnitus occur-
rence in CCS compared to siblings was 3.0 (95% CI 2.9–
3.1), adjusted for gender and age at the questionnaire. In 
total, 82/280 (29%) of the CCS with tinnitus wore a hearing 
aid (3% of the total CCS cohort) compared to 2/40 (5%) sib-
lings (0.2% of the total siblings cohort). Tinnitus most often 
occurred in CCS who had been diagnosed with osteosar-
coma (18/86% = 21%), CNS tumors (57/353 = 16%), Ewing 
sarcoma (11/81  =  14%), and other tumors (7/41  =  17%; 
Supplementary Table 3).
Risk Factors Associated With Tinnitus in CCS
In Table 3, estimated ORs from univariate and multivariate 
logistic regression models are provided. The univariate 
analysis showed that tinnitus occurrence in CCS was as-
sociated with age at diagnosis, neuro/ENT surgery, (total 
dose) cranial irradiation/TBI, and (TCD) cisplatin, but not 
with gender and (TCD) carboplatin.
Two multivariate logistic regression models were es-
timated. Model 1 included cranial irradiation/TBI and cis-
platin treatment as dichotomous variables (yes/no); in 
model 2, total dose of cranial irradiation (<50 Gy and ≥50 
Gy) and TCD of cisplatin (<400  mg/m2 and ≥400  mg/m2) 
were included using CCS without these treatments as the 
reference category.
Multivariate model 1 revealed that tinnitus occurrence was 
significantly associated with age at diagnosis (≥10  years: 
OR 2.1, 95% CI 1.5–2.8), cisplatin treatment (OR 2.0, 95% CI 
1.4–3.0), cranial irradiation/TBI (OR 1.9, 95% CI 1.5–2.5), and 
neuro/ENT surgery (OR 1.8, 95% CI 1.1–2.8). Multivariate 
model 2 identified TCD cisplatin ≥400 mg/m2 (OR 2.4, 95% CI 
1.4–4.0), age at diagnosis (≥10 years: OR 2.1, 95% CI 1.6–2.8), 
 No 2668 (90.5) 1015 (96.3)  
 Yes 280 (9.5) 40 (3.7)  
Age at start tinnitus in 
yearsd, n (%)
  .003
 ≤30 98 (67.1) 16 (47.1)  
 >30 48 (32.9) 18 (52.9)  
Hearing aid usee, n 
(%)
  <.001
 No 2813 (95.6) 1047 (99.3)  
 Yes 129 (4.4) 7 (0.7)  
Age at hearing aid 
use in yearsf, n (%)
  NAg
 ≤30 39 (78.0) 2 (28.6)  
 >30 11 (22.0) 5 (71.4)  
CCS, childhood cancer survivors; NA, not applicable.
aIncluding chronic myeloproliferative diseases, myelodysplastic syn-
drome, and unspecified/other leukemias.
bIncluding Burkitt lymphomas, miscellaneous lymphoreticular neo-
plasms, and unspecified lymphomas. 
cN = 8 missings for siblings.
dN = 134 missings for survivors and N = 6 missings for siblings.
eN = 6 missings for survivors and N = 1 for siblings.
fN = 79 missings for survivors.




Table 2. Treatment Characteristics of the Total Cohort of CCS, 








Surgery, n (%)    
 No surgery 980 (33.2) 86 (30.7) 894 (33.5)
 Neuro/ENT surgery 150 (5.1) 27 (9.6) 123 (4.6)
 Other surgery 1818 (61.7) 167 (59.6) 1651 (61.9)
Radiotherapy, n (%)    
 No irradation 1801 (61.1) 127 (45.5) 1674 (62.7)
  Cranial irradiation 
incl. total body  
irradiation
698 (23.7) 105 (37.5) 593 (22.2)
  Other irradiation 
site
449 (15.2) 48 (17.1) 401 (15.0)
Chemotherapy, n (%)    
 No 476 (16.1) 61 (21.8) 415 (15.6)
 Yes 2472 (83.9) 219 (78.2) 2253 (84.4)
Alkylating agents, 
n (%)
   
 No 1528 (51.8) 141 (50.4) 1279 (47.9)
 Yes 1420 (48.2) 139 (49.6) 1389 (52.1)
Anthracyclines, n (%)    
 No 1578 (53.5) 174 (62.1) 1404 (52.6)
 Yes 1370 (46.5) 106 (37.9) 1264 (47.4)
Platinum agents, n 
(%)
   
 No 2574 (87.3) 233 (83.2) 2341 (87.7)
 Yes 374 (12.7) 47 (16.8) 327 (12.3)
Vinca-alkaloids, n (%)    
 No 740 (25.1) 98 (35.0) 642 (24.1)
 Yes 2208 (74.9) 182 (65.0) 2026 (75.9)
Antimetabolites, n 
(%)
   
 No 1549 (52.5) 156 (55.7) 1393 (52.2)
 Yes 1399 (47.5) 124 (44.3) 1275 (47.8)
Epipodophyllotoxins, 
n (%)
   
 No 2363 (80.2) 233 (83.2) 2130 (79.8)
 Yes 585 (19.8) 47 (16.8) 538 (20.2)
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Table 3. Risk Factors Associated With Tinnitus Comparing CCS With and Without Tinnitus, Univariate and Multivariate Results
Tinnitus + Tinnitus− UVA MVAa MVAb
 N = 280 (%) N = 2668 (%) OR (95% CI) OR (95% CI) OR (95% CI)
Gender      
 Male 151 (54) 1372 (51) REF   
 Female 129 (46) 1296 (49) 0.9 (0.7–1.2) - -
Age at diagnosis      
 <5 years 96 (34) 1283 (48) REF REF REF
 5–9 years 72 (26) 717 (27) 1.3 (1.0–1.8)* 1.2 (0.9–1.7) 1.2 (0.9–1.7)
 10+ years 112 (40) 668 (25) 2.2 (1.7–3.0)* 2.1 (1.5–2.8)** 2.1 (1.6–2.8)**
Neuro/ENT surgery      
 No 253 (90) 2545 (95) REF REF REF
 Yes 27 (10) 123 (5) 2.2 (1.4–3.4)* 1.8 (1.1–2.8)** 1.8 (1.1–2.9)**
Cranial irradiation/TBI      
 No 175 (63) 2075 (78) REF REF  
 Yes 105 (37) 593 (22) 2.1 (1.6–2.7)* 1.9 (1.5–2.5)** -
TD cranial irradiation/TBI      
 No irradiation 175 (63) 2075 (78) REF  REF
 <50 Gy 62 (22) 391 (15) 1.9 (1.4–2.6)* - 1.9 (1.4–2.7)**
 ≥50 Gy 42 (15) 193 (7) 2.6 (1.8–3.7)*  1.9 (1.3–2.9)**
TD cranial irradiation/TBI      
 <50 Gy 62 (60) 391 (67) REF   
 ≥50 Gy 42 (40) 193 (33) 1.4 (0.9–2.1) - -
Carboplatin      
 No 263 (94) 2487 (93) REF   
 Yes 17 (6) 181 (7) 0.9 (0.5–1.5) - -
TCD carboplatin      
 No carboplatin 263 (94) 2.487 (93) REF   
 <1500 mg/m2 5 (2) 50 (2) 0.9 (0.4–2.4) - -
 ≥1500 mg/m2 11 (4) 125 (5) 0.8 (0.4–1.6)   
TCD carboplatin      
 <1500 mg/m2 5 (31) 50 (29) REF - -
 ≥1500 mg/m2 11 (69) 125 (71) 0.9 (0.3–2.7)   
Cisplatin      
 No 243 (87) 2499 (94) REF REF  
 Yes 37 (13) 169 (6) 2.3 (1.5–3.3)* 2.0 (1.4–3.0)** -
TCD cisplatin      
 No cisplatin 243 (87) 2499 (94) REF  REF
 <400 mg/m2 15 (5) 69 (3) 2.2 (1.3–4.0)* - 1.8 (0.9–3.2)
 ≥400 mg/m2 21 (8) 91 (3) 2.3 (1.5–3.9)*  2.4 (1.4–4.0)**
TCD cisplatin      
 <400 mg/m2 15 (42) 69 (43) REF   
 ≥400 mg/m2 21 (58) 91 (57) 1.1 (0.5–2.2) - -
CCS, childhood cancer survivors; CI, confidence interval; MVA, multivariate analysis; OR, odds ratio; REF, reference; TBI, total body irradiation; TD, 
total dose; TCD, total cumulative dose; UVA, univariate analysis.
aModel with cranial irradiation and cisplatin.
bModel with cranial irradiation dose and cisplatin dose (patients without treatment as reference group).
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and neuro/ENT surgery (OR 1.8, 95% CI 1.1–2.9) as inde-
pendent factors for tinnitus occurrence. The ORs for tinnitus 
occurrence were the same (OR 1.9) for the 2 subgroups ac-
cording to cranial irradiation dose (<50 Gy/≥50 Gy).
Additional Risk Factors for Tinnitus in CCS
A total of 142/280 (51%) CCS with tinnitus had received ei-
ther cisplatin, cranial irradiation/TBI, and/or neuro/ENT sur-
gery, whereas 138/280 (49%) had not (Supplementary Figure 
1). The latter group of CCS had frequently been treated be-
tween 1985 and 1994, were often aged 5 years or younger at 
the time of diagnosis and 30 years or younger at the time of 
questionnaire. Furthermore, they wore a hearing aid (50/138, 
36%) more often than CCS who had received cisplatin, cranial 
irradiation/TBI, or neuro/ENT surgery (32/142, 23%), and CCS 
without tinnitus (47/2668, 2%; Supplementary Table 3).
In the subpopulation of ALL survivors, tinnitus occurred in 
72/888 (8%) CCS (Supplementary Figure 2) compared to 9/320 
(3%) siblings (OR 3.3, 95% CI 3.2–3.4), adjusted for gender and 
age at questionnaire. A total of 281/888 (32%) ALL survivors re-
ceived cranial irradiation/TBI, whereas 607/888 (68%) had not. 
Among them, 32/72 (44%) CCS with tinnitus had received cra-
nial irradiation/TBI (Supplementary Figure 1). Univariate anal-
ysis showed that ALL survivors had a higher risk of tinnitus 
when they were treated before 1985 (OR 2.2, 95% CI 1.2–4.0), 
were 10 years or older at the time of diagnosis (OR 2.1, 95% 
CI 1.2–3.8), and/or had received cranial irradiation/TBI (OR 1.8, 
95% CI 1.1–3.0). According to the multivariate analysis, age at 
diagnosis and cranial irradiation/TBI were significantly associ-
ated with tinnitus occurrence in ALL survivors (OR 2.1, 95% CI 
1.1–3.8; OR 1.8, 95% CI 1.1–3.0, respectively).
Among survivors who had been diagnosed with 
CNS tumors, tinnitus occurred in 57/353 (16%) CCS 
(Supplementary Figure 2), compared to 1/111 (0.9%) 
siblings. Most of the CCS with tinnitus had been diag-
nosed with medulloblastoma (N  =  22, 39%), low-
grade astrocytoma (N  =  13, 23%), and non-low-grade 
astrocytoma (N = 10, 18%). In total, 210/353 (59%) CCS had 
received cranial irradiation (39/57 [68%]: with tinnitus), 
34/353 (10%) CCS had received cisplatin (8/57 [14%]: with 
tinnitus), 68/353 (19%) CCS had received carboplatin (8/57 
[14%]: with tinnitus), and 108/353 (31%) had received 
neuro/ENT surgery (21/57 [37%]: with tinnitus). Univariate 
analysis showed that CNS tumor survivors had a higher 
risk of tinnitus when they were treated before 1985 (OR 
2.9, 95% CI 1.3–6.3), were of male gender (OR 1.5, 95% CI 
0.8–2.6), were 10 years or older at time of diagnosis (OR 
1.8, 95% CI 0.9–3.8), and/or had received cranial irradia-
tion (OR 1.6, 95% CI 0.9–2.9). In the multivariate analyses, 
only the treatment period remained significantly associ-
ated with tinnitus occurrence in CNS tumor survivors (be-
fore 1985: OR 2.6, 95% CI 1.2–5.9).
Discussion
This study explored the occurrence of and risk factors for 
tinnitus in a national cohort of CCS. Our results revealed 
that tinnitus occurred in 9.5% of CCS, and they were nearly 
3 times more likely to suffer from tinnitus compared to sib-
lings. Age at diagnosis, neuro/ENT surgery, cranial irradi-
ation/TBI, and cisplatin (TCD ≥400 mg/m2) were identified 
as independent risk factors. The latter treatment modalities 
had been administered to about 50% of the CCS who re-
ported tinnitus, which suggests that also other factors 
might be associated with the occurrence of tinnitus in this 
population.
To date, many studies investigating audiological acute 
and late effects of childhood cancer treatment have fo-
cused on hearing loss. However, information on the fre-
quency of and risk factors for tinnitus during and after 
childhood cancer based on national cohort studies is lim-
ited. In the few available studies, tinnitus was reported to 
occur in 3–60% of CCS.11,13–21 Variation in study sample size, 
type of childhood cancer, age at diagnosis, cancer treat-
ment, and time to follow-up may have influenced these re-
sults. Our recently published systematic review22 included 
a risk of bias assessment by use of the QUIPS tool23 among 
the available studies on tinnitus during and after child-
hood cancer, which revealed a smaller range of tinnitus in 
studies of adequate quality (3–17%).11,13–17 However, evi-
dence for risk factors of tinnitus within these studies was 
scarce, indicating that more research was needed. For 
that purpose, the current study was entirely focused on 
identifying tinnitus and its risk factors, and it was shown 
that the estimated proportion of 9.5% in CCS is higher than 
in controls.
The results of this study indicate that CCS had more 
odds of developing tinnitus compared to a sibling control 
group that was relatively older. This finding is important 
as tinnitus can have a large negative impact on quality of 
life. Adults with bothersome ringing in the ears often have 
to cope with accompanying symptoms such as concen-
tration problems and insomnia, which are known to fre-
quently lead to depression, anxiety, and mental distress. 
Consequently, work performance and social participation 
can be affected.24 Clinical management strategies that 
can be helpful for a subset of tinnitus patients are avail-
able. This includes mainly psychological treatment such as 
cognitive behavioral therapy and/or auditory stimulation 
by the use of hearing aids or personal listening devices.25 
Auditory stimulation restores or enhances afferent input 
to the auditory neural pathways by providing or ampli-
fying (environmental) sounds, leading to downregulation 
of spontaneous neural activity, and thereby reducing the 
comparative loudness of tinnitus in quiet environments.26 
Regular surveillance may be helpful for increased aware-
ness, (early) detection, referral, and treatment of tinnitus 
in CCS.
A high TCD cisplatin was associated with tinnitus occur-
rence in CCS. This finding is in agreement with the results 
of previous studies with smaller sample sizes. Cisplatin 
harms the outer hair cells (OHCs) in the cochlea by dam-
aging DNA and increasing the release of reactive oxygen 
species,27 especially when the drug is administered in high 
TCDs of 400 mg/m2 or more.12 Carboplatin did not appear 
to be associated with tinnitus in the current study. This 
platinum agent has ototoxic potential but generally causes 
less cochlear damage compared to cisplatin,28 which may 
explain the low frequency of tinnitus in CCS treated with 
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irradiation/TBI was associated with the occurrence of tin-
nitus, but not the total radiation dose. Radiotherapy leads 
to changes in cochlear OHCs and vascular degeneration 
and decreases the function of the basilar membrane and 
cochlear nerve.29 To date, conflicting results have been 
reported regarding the effect of total radiation dose on 
tinnitus presence.11,13,15 It will be important to include do-
simetry in future studies to determine the specific radia-
tion dosages on the cochlea and possibly other relevant 
structures such as the VIII cranial nerve for a better risk 
estimation of tinnitus development. Lastly, neuro/ENT 
surgery was identified as a risk factor for tinnitus in CCS. 
Previous smaller studies have shown that cochlear or 
neural damage might be related to surgical resection of a 
CNS tumor and insertion of a cerebrospinal fluid shunt.4 
As high TCDs cisplatin, cranial irradiation, and neuro/
ENT surgery are used in various childhood cancer treat-
ment protocols, increased awareness for tinnitus develop-
ment in pediatric oncology patients and survivors seems 
warranted.
About half of CCS with tinnitus had not received cis-
platin, cranial irradiation/TBI, and/or neuro/ENT surgery, 
suggesting that other factors might be associated with 
tinnitus in this subpopulation. Among CCS, the median 
time from cancer diagnosis to questionnaire comple-
tion was comparatively long (22 years). During this time, 
several other conditions underlying tinnitus symptoms, 
which commonly occur in the general population, could 
have been developed. These include otologic disorders 
(eg, otosclerosis, Menière’s disease), neurological con-
ditions (eg, head injury, whiplash, multiple sclerosis), 
infectious diseases (eg, otitis media, Lyme disease, men-
ingitis), and temporomandibular joint dysfunction as well 
as other dental disorders.30 Furthermore, increasing age 
of CCS could have been associated with tinnitus devel-
opment. The aging process causes changes in adaptive 
and compensatory neural mechanisms in the brain, and 
the presence of tinnitus and its perception might depend 
upon these mechanisms. It seems that the efficiency 
of this compensatory mechanism decreases with age, 
making older individuals more aware of tinnitus.31 Lastly, 
frequent exposure to excessive noise (levels of 90 dB or 
higher) can induce tinnitus by progressive cochlear hair 
cell destruction. Noise exposure can be related to work 
(eg, loud machinery), music at hazardous volume (eg, at 
concerts, night clubs, or from personal listening devices), 
or trauma (eg, a sudden loud bang or explosion).32 The 
physiological risk of tinnitus in the general population 
might be represented in the subgroup of CCS with tin-
nitus but without treatment-related risk factors. It should 
be mentioned that siblings in this study were relatively 
older at the time of questionnaire compared to CCS, 
indicating that they also might have been exposed to one 
or more factors mentioned above. Nevertheless, the pro-
portion of tinnitus in siblings remains lower compared 
to CCS.
In the largest diagnostic subcohort of ALL survivors, 8% 
suffered from tinnitus, and of them, 56% had not been ir-
radiated. Up to 1985, all pediatric leukemia patients in 
the Netherlands received cranial irradiation, whereafter it 
was only applied in high-risk patients with CNS involve-
ment.33 Another possible risk factor for tinnitus in these 
ALL survivors could be the administration of intrathecal 
therapy, which has substituted cranial irradiation in a more 
recent treatment era. It is known that this CNS-directed 
therapy increases the risk of neurologic toxicities,34 and a 
small study reported an association between intrathecal 
methotrexate and auditory pathway impairment in the 
brainstem.35 Furthermore, fluid overload and infections are 
important complications during ALL treatment, for which 
respectively diuretics and antibiotics are often applied. 
Many of these agents are potentially ototoxic, including 
aminoglycosides (eg, gentamicin, tobramycin), loop di-
uretics (eg, furosemide), and glycopeptides (eg, vanco-
mycin).27 The specific role of these agents to be associated 
with cochlear damage without concomitant administration 
of platinum agents and cranial irradiation needs to be de-
termined. The Dutch LATER study was not designed to cap-
ture co-medication use during childhood cancer treatment. 
Prospective studies are necessary to investigate the role of 
intrathecal therapy and co-medication on tinnitus develop-
ment in children with cancer.
To the best of our knowledge, this is the first study in 
CCS that was entirely dedicated to tinnitus, based on 
a large national cohort. The inclusion of siblings as a 
healthy control group was beneficial as CCS and siblings 
broadly have the same genetic and socio-demographic 
profile.36 Strong conclusions on the reason for and ben-
efit of hearing aid use cannot be drawn from this study 
(Supplementary Table 4), as the Dutch LATER study was 
neither designed to capture data on nor to study hearing 
loss. In addition, as tinnitus can only be heard by an af-
fected individual, it can only be reported in a subjective 
manner. In the current study, the general health question-
naire was designed to gain insight into the presence of 
tinnitus in CCS but not on its severity or laterality, leaving 
it unsure how many mild, moderate, or severe tinnitus 
cases were identified, and whether there were more uni-
lateral or bilateral tinnitus cases in our cohort. Therefore, 
it would be useful to include validated tinnitus question-
naires as part of standard toxicity screening in CCS in 
order to scale the severity and negative impact of tinnitus. 
The question on age or year of tinnitus onset could have 
caused recall bias, as it might have been difficult for CCS 
to remember when tinnitus had developed over time. 
Potential selection bias may have occurred as 63% of the 
CCS who were eligible for the questionnaire participated 
in the study, which might have limited the generalizability 
of the results. However, we found no statistical differ-
ences between CCS who completed the item on tinnitus 
and CCS who did not.
In conclusion, this study reveals that tinnitus more 
often occurs in CCS compared to healthy siblings. 
Awareness of tinnitus in survivors who have been 
treated with cisplatin, cranial irradiation/TBI, and/or 
neuro/ENT surgery is warranted among health care pro-
fessionals. However, these treatment modalities only ex-
plain the presence of tinnitus in about half of the CCS. 
This suggests that other (co-treatment) factors may be 
involved in tinnitus development in this population, 
which should be further investigated in future (late ef-
fects) studies. Our data show that tinnitus as part of 
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